🧐 ProPicks AI October update is out now! See which stocks made the listPick Stocks with AI

Emergent Biosolutions Inc (EBS)

NYSE
Currency in USD
Disclaimer
9.350
+0.410(+4.59%)
Closed
After Hours
9.210-0.140(-1.497%)
EBS Scorecard
Full Analysis
High shareholder yield
Fair Value
Day's Range
8.8609.570
52 wk Range
1.42015.100
Prev. Close
8.94
Open
9.04
Day's Range
8.86-9.57
52 wk Range
1.42-15.1
Volume
1,635,131
Average Volume (3m)
3,098,119
1-Year Change
212.71%
Book Value / Share
Unlock
Fair Value
Unlock
Fair Value Upside
Unlock
EBS Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
8.000
Downside
-14.439%
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week
Show more

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Employees
2500

Compare EBS to Peers and Sector

Metrics to compare
EBS
Peers
Sector
Relationship
P/E Ratio
−0.9x−1.5x−0.6x
PEG Ratio
−0.140.000.00
Price/Book
1.3x2.2x2.6x
Price / LTM Sales
0.5x27.9x3.2x
Upside (Analyst Target)
−14.4%285.2%40.8%
Fair Value Upside
Unlock23.0%5.9%Unlock

FAQ

What Is the Emergent Biosolutions (EBS) Stock Price Today?

The Emergent Biosolutions stock price today is 9.35.

What Stock Exchange Does Emergent Biosolutions Trade On?

Emergent Biosolutions is listed and trades on the NYSE stock exchange.

What Is the Stock Symbol for Emergent Biosolutions?

The stock symbol for Emergent Biosolutions is "EBS."

What Is the Emergent Biosolutions Market Cap?

As of today, Emergent Biosolutions market cap is 505.09M.

What is Emergent Biosolutions Earnings Per Share?

The Emergent Biosolutions EPS is -11.26.

What Is the Next Emergent Biosolutions Earnings Date?

Emergent Biosolutions will release its next earnings report on 05 Nov 2024.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.